Related Experiment Video
Updated: Oct 20, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
The NCI-EORTC Symposia on New Drugs in Cancer Therapy: A Brief History
Krul1
1EORTC New Drug Development Office, Free University Hospital, 1007 MB Amsterdam, The Netherlands. krul@eortc.nl
Abstract:
HISTORY OF THE SERIES: Two organizations that made a major contribution to the discovery and development of potential new anticancer agents are the NCI (United States National Cancer Institute) and the EORTC (European Organization for Research and Treatment of Cancer). A series of specialized symposia, the NCI-EORTC Symposia on New Drugs in Cancer Therapy, has been dedicated to this theme. The first four symposia were held in Brussels, Belgium, and were organized by Dr. Marcel Rozencweig. In 1984, after Dr. H.M. Pinedo had established the EORTC New Drug Development Office (NDDO) in Amsterdam, the symposium moved to Amsterdam as well. All subsequent symposia were organized by the NDDO, with Dr. Pinedo as symposium President, starting with the 5th NCI-EORTC Symposium on New Drugs in Cancer Therapy in October 1986. Since then, the symposium has seen a strong growth to over 1,750 participants from 50 countries at this year's meeting. This growth has been achieved not only by increased participation from European countries, but there has been an even stronger increase in the number of participants from other continents, notably North America and the Far East. Approximately one-third of the participants were non-European. The series has achieved a truly global scale and provides an excellent forum to everyone involved in the research and development of new anticancer agents which nowadays tends to occur in a worldwide setting.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
07:54Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Clinical Trials: Overview